"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
The clinical effects of overdosing with Prussian blue insoluble are not known. Based on reported adverse events and mechanism of action, possible overdose symptoms may include obstipation, obstruction, or severe decrease in electrolytes.
Last reviewed on RxList: 10/1/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Radiogardase Information
Report Problems to the Food and Drug Administration
Find out what women really need.